Use of UMFNPs/Ce6@MBs in multimodal imaging-guided sono-photodynamic combination therapy for hepatocellular carcinoma
Early diagnosis of liver cancer and appropriate treatment options are critical for obtaining a good prognosis. However, due to technical limitations, it is difficult to make an early and accurate diagnosis of liver cancer, and the traditional imaging model is relatively simple. Therefore, we synthesized multifunctional diagnostic/therapeutic nanoparticles, UMFNPs/Ce6@MBs, loaded with ultra-small manganese ferrite nanoparticles (UMFNPs) and chlorin e6 (Ce6). This nanoplatform can take full advantage of hypoxia, acidic pH (acidosis) and increased levels of reactive oxygen species (<i>e.g.</i> H<sub>2</sub>O<sub>2</sub>) in the tumor microenvironment (TME). Specific imaging and drug release can also enhance tumor therapy by modulating the hypoxic state of the TME to achieve the combined effect of sonodynamic therapy and photodynamic therapy (SPDT). In addition, the prepared UMFNPs/Ce6@MBs have H<sub>2</sub>O<sub>2</sub> and pH-sensitive biodegradability and can release UMFNPs and photosensitizer Ce6 in the TME while producing O<sub>2</sub> and Mn<sup>2+</sup>. The obtained Mn<sup>2+</sup> ion nanoparticles can be used for <i>T</i><sub>1</sub> magnetic resonance imaging of tumor-bearing mice, and the released Ce6 can provide fluorescence imaging function at the same time. Because UMFNPs/Ce6@MB ultrasonic microbubbles show good ultrasonic imaging results, UMFNPs/Ce6@MBs can simultaneously provide multi-modal imaging functions for magnetic resonance imaging (MRI), ultrasound and fluorescence imaging. In conclusion, UMFNPs/Ce6@MBs realize the synergistic treatment of SDT and PDT under multi-mode near-infrared fluorescence imaging and CEUS monitoring, demonstrating its great potential in tumor precision medicine.
Authors
- Bingxuan Xu (ORCID: https://orcid.org/0000-0003-0921-899X)
- Qing Dan
- Xintao Shuai (ORCID: https://orcid.org/0000-0003-4271-0310)
- Keyan Yu
- Xiaoting Yang (ORCID: https://orcid.org/0000-0002-4177-4876)
- Jianhua Bai
- Guanxun Cheng (ORCID: https://orcid.org/0000-0001-9168-1670)
- Yulong Qi (ORCID: https://orcid.org/0000-0002-1413-4064)
- Lijun Xing
- Li Li (ORCID: https://orcid.org/0000-0002-4712-2692)
- Xiaoyu Chen (ORCID: https://orcid.org/0000-0002-3398-7804)
- Yun Chen (ORCID: https://orcid.org/0000-0001-9693-9722)
- Li Liu (ORCID: https://orcid.org/0000-0003-2314-8756)
- Tingting Zheng (ORCID: https://orcid.org/0000-0003-0424-0231)
- Jing Cai (ORCID: https://orcid.org/0000-0003-3758-3337)
- Chunting Zhong (ORCID: https://orcid.org/0009-0008-9332-7139)
- Yiran Ji
Institutions
- Hubei University of Medicine (CN)
- Sun Yat-sen University (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Peking University Shenzhen Hospital (CN)
- University of Hong Kong - Shenzhen Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Biomaterials Science
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1039/d4bm00613e
- Citations
- 7
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Natural Science Foundation of Guangdong Province
- Peking University
- Sanming Project of Medicine in Shenzhen
- Shenzhen Fundamental Research and Discipline Layout project